SAN DIEGO, August 6, 2025 — Leads & Copy — AnaptysBio, Inc. (Nasdaq: ANAB) reported positive data for rosnilimab from a Phase 2b rheumatoid arthritis trial through Week 38. Enrollment is complete for the rosnilimab Phase 2 ulcerative colitis trial, with top-line data expected in Q4 2025. Phase 1 trials are ongoing for ANB033 and ANB101. A Phase 1b cohort for ANB033 in celiac disease is planned for Q4 2025. Anaptys anticipates a $75 million milestone from GSK in 2025.
According to Daniel Faga, president and chief executive officer of Anaptys, the company is excited to announce the initial indication for its CD122 antagonist, ANB033, is celiac disease (CeD), a serious autoimmune disease triggered by the ingestion of gluten, affecting more than 2.1 million people in the U.S. but with no approved therapies.
AnaptysBio’s cash and investments totaled $293.7 million as of June 30, 2025. The company has repurchased 2,853,836 shares of common stock with $55.5 million from its $75.0 million Stock Repurchase Program.
Nick Montemarano
Executive Director, Investor Relations
858.732.0178
investors@anaptysbio.com
Source: AnaptysBio
